Details:
Under the agreement, Amneal will have exclusive rights to market and distribute ONGENTYS (opicapone), a highly-selective COMT inhibitor, which is approved by USFDA as an add-on treatment to carbidopa/levodopa in patients with Parkinson’s disease experiencing Off episodes.
Lead Product(s): Opicapone
Therapeutic Area: Neurology Product Name: Ongentys
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Amneal Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 07, 2023
Details:
BIAL takes the lead for the marketing and distribution of Zebinix® (eslicarbazepine acetate) in Europe. Eslicarbazepine acetate is a once-daily anti-epileptic used to treat epilepsy patients with focal seizures (partial-onset seizures).
Lead Product(s): Eslicarbazepine Acetate
Therapeutic Area: Neurology Product Name: Zebinix
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Eisai
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination February 17, 2021